We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESRX
76
DELISTED
Express Scripts Holding Company
ESRX
$7.36M 0.29%
106,500
+22,000
+26% +$1.68M
DHR icon
77
Danaher
DHR
$138B
$7.33M 0.29%
84,427
+67,278
+392% +$5.89M
IONS icon
78
Ionis Pharmaceuticals
IONS
$8.81B
$7.3M 0.28%
165,677
+36,747
+29% +$1.87M
SNR
79
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$7.23M 0.28%
883,919
– –
SNY icon
80
Sanofi
SNY
$103B
$7.21M 0.28%
179,900
– –
BPMC
81
DELISTED
Blueprint Medicines
BPMC
$6.81M 0.26%
+74,221
New +$6.4M
NVO
82
Novo Nordisk
NVO
$228B
$6.69M 0.26%
271,800
-271,800
-50% -$7.14M
CRSP icon
83
CRISPR Therapeutics
CRSP
$4.77B
$6.45M 0.25%
+141,191
New +$5.83M
GBT
84
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.28M 0.24%
129,948
– –
AVDL
85
DELISTED
Avadel Pharmaceuticals
AVDL
$5.94M 0.23%
814,588
+190,300
+30% +$1.67M
ISRG icon
86
Intuitive Surgical
ISRG
$126B
$5.87M 0.23%
42,654
+31,104
+269% +$4.34M
VRNA
87
DELISTED
Verona Pharma
VRNA
$5.5M 0.21%
275,000
– –
ENDP
88
DELISTED
Endo International plc
ENDP
$5.43M 0.21%
914,548
– –
WMGI
89
DELISTED
Wright Medical Group Inc
WMGI
$5.29M 0.21%
266,781
– –
KYNB
90
Kyntra Bio
KYNB
$27.5M
$4.82M 0.19%
+4,172
New +$5.49M
FOMX
91
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.77M 0.19%
930,398
– –
QURE icon
92
uniQure
QURE
$2.93B
$4.69M 0.18%
199,750
-133,100
-40% -$2.9M
UTHR icon
93
United Therapeutics
UTHR
$26.2B
$4.64M 0.18%
41,261
+25,041
+154% +$3.18M
NVRO
94
DELISTED
NEVRO CORP.
NVRO
$4.59M 0.18%
52,990
-141,631
-73% -$11.4M
EDIT icon
95
Editas Medicine
EDIT
$413M
$4.57M 0.18%
+137,801
New +$4.91M
VTR icon
96
Ventas
VTR
$44.7B
$4.36M 0.17%
87,996
– –
BHVN
97
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.18M 0.16%
+162,477
New +$4.86M
DOC
98
DELISTED
PHYSICIANS REALTY TRUST
DOC
$4.13M 0.16%
265,336
– –
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$4.07M 0.16%
+125,000
New +$4.21M
THC icon
100
Tenet Healthcare
THC
$21.8B
$3.99M 0.16%
164,500
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.